Neurocrine Biosciences (NBIX) EBIT (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported EBIT for 17 consecutive years, with $151.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 4.05% year-over-year to $151.5 million; the trailing twelve-month figure through Jun 2026 stood at $794.8 million (up 60.57% YoY), and the FY2025 full-year result was $619.1 million, up 8.52% from the prior year.
• EBIT eased to $151.5 million in Q2 2026 per NBIX's latest filing, from $193.4 million in the prior quarter.
• Across five years, EBIT topped out at $239.0 million in Q3 2025 and bottomed at -$114.2 million in Q1 2023.
• Historically, EBIT has averaged $113.0 million across 5 years, with a median of $141.6 million in 2023.
• The sharpest annual moves came in 2023 and 2026: EBIT plunged 3783.87% in 2023, then surged 719.49% in 2026.
• Over 5 years, EBIT stood at $103.4 million in 2022, then surged by 45.36% to $150.3 million in 2023, then decreased by 5.52% to $142.0 million in 2024, then surged by 48.52% to $210.9 million in 2025, then retreated by 28.17% to $151.5 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $151.5 million, $193.4 million, and $210.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.